IgA Nephropathy Market to Reach New Heights by 2036 as Novartis Zigakibart and Novel Immunotherapies Drive Growth

Key Takeaways

• IgA nephropathy market projected for significant growth through 2036, fueled by novel immunotherapy pipeline including Novartis’ Zigakibart
• Multiple pharmaceutical giants including Roche, Vertex, and AstraZeneca advancing promising treatments in clinical trials
• Rising disease prevalence and improved diagnostic capabilities creating expanded patient population for targeted therapies

---

New York, April 29, 2026 — The IgA nephropathy (IgAN) therapeutic market is positioned for substantial expansion through 2036, driven by breakthrough immunotherapies and an increasingly robust clinical pipeline, according to new market analysis from DelveInsight.

Pipeline Momentum Accelerates Market Growth

The IgAN market transformation centers on several high-potential therapies advancing through clinical development. Novartis’ Zigakibart leads the immunotherapy charge, targeting specific pathways involved in IgA nephropathy progression. Concurrently, Roche and Ionis Pharmaceuticals’ collaborative Sefaxersen represents another promising approach to treating this chronic kidney condition.

Vertex Pharmaceuticals’ Povetacicept and AstraZeneca’s ULTOMIRIS further strengthen the competitive landscape, while Vera Therapeutics’ Atacicept offers additional therapeutic mechanisms for patients with limited treatment options.

Market Drivers Reshape Treatment Landscape

Several key factors contribute to the projected market expansion. Rising IgA nephropathy prevalence, particularly in Asian populations where the condition affects up to 45% of glomerulonephritis cases, creates substantial unmet medical need. Enhanced diagnostic capabilities enable earlier disease detection, expanding the treatable patient population.

The shift toward precision immunotherapies marks a departure from traditional supportive care approaches. These targeted treatments address underlying disease mechanisms rather than merely managing symptoms, potentially slowing kidney function decline and reducing progression to end-stage renal disease.

Clinical Development Accelerates

Ongoing clinical trials across multiple therapeutic classes demonstrate industry commitment to addressing IgAN’s complex pathophysiology. The diverse mechanism portfolio—from complement inhibition to B-cell targeting—suggests multiple pathways to therapeutic success.

Improved understanding of IgAN’s immunological basis has enabled more sophisticated drug development approaches. This scientific advancement, combined with regulatory support for rare kidney disease treatments, creates favorable conditions for market growth through the next decade.

---

Frequently Asked Questions

What does this mean for IgA nephropathy patients?

Patients will have access to multiple new treatment options that target the underlying disease mechanisms rather than just managing symptoms, potentially slowing kidney function decline and improving long-term outcomes.

When will Zigakibart and other new treatments be available?

Timeline depends on clinical trial results and regulatory approval processes. Most therapies are currently in various phases of clinical development, with potential market entry spanning the next several years through 2036.

How do these new therapies compare to existing IgA nephropathy treatments?

Current treatments focus primarily on blood pressure control and symptom management. These new immunotherapies target specific disease pathways, offering potential for disease modification rather than just supportive care.